ACM
RGLS

Argonaut Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Argonaut Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$491K Buy
+625
New +$641K 1.65% 23

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Argonaut Capital Management's RGLS Position: Q3 2015 in Review

Argonaut Capital Management opened a new position in Regulus Therapeutics (RGLS) in Q3 2015: 625 shares worth $491K. The stake represents 1.65% of the portfolio and ranks #23 among its holdings.

92 funds tracked by Wall St. Rank hold RGLS as of Q3 2015.

  • Argonaut Capital Management held 625 shares of Regulus Therapeutics worth $491K as of Q3 2015.
  • Regulus Therapeutics was a new Argonaut Capital Management position in Q3 2015.
  • Regulus Therapeutics made up 1.65% of Argonaut Capital Management's portfolio in Q3 2015, its #23 holding.
  • 92 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2015.

Based on Argonaut Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.